PTHS
Channel Therapeutics Corporation (PTHS)
Healthcare • NYSE MKT • $19.83-1.61%
- Symbol
- PTHS
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $19.83
- Daily Change
- -1.61%
- Market Cap
- $77.14M
- Trailing P/E
- N/A
- Forward P/E
- -3.92
- 52W High
- $37.50
- 52W Low
- $18.19
- Analyst Target
- $51.71
- Dividend Yield
- 0.00%
- Beta
- 3.11
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 20…
Company websiteResearch PTHS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.